Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases

BACKGROUND: In the INBUILD trial in patients with chronic fibrosing interstitial lung diseases (ILDs) and a progressive phenotype, nintedanib reduced the rate of ILD progression with adverse events that were manageable for most patients. We investigated the potential impact of immunomodulatory thera...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Respir Res
Main Authors: Cottin, Vincent, Richeldi, Luca, Rosas, Ivan, Otaola, Maria, Song, Jin Woo, Tomassetti, Sara, Wijsenbeek, Marlies, Schmitz, Manuela, Coeck, Carl, Stowasser, Susanne, Schlenker-Herceg, Rozsa, Kolb, Martin
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2021
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7962343/
https://ncbi.nlm.nih.gov/pubmed/33726766
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-021-01668-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados